Here are relevant reports on : cell-therapy-market
-
Cell Therapy Technologies Market by Product (Media, Sera, Reagents, Vessels, Equipment), Process (Expansion, Isolation, Characterization, Collection, Preservation, Distribution, QC), Type (T-cells, Stem Cells), Application (Cancer) - Global Forecast to 2030
The global cell therapy technologies market, valued at US$4.05 billion in 2024, stood at US$4.41 billion in 2025 and is projected to advance at a resilient CAGR of 12.4% from 2024 to 2030, culminating in a forecasted valuation of US$7.91 billion by the end of the period.
- Published: December 2025
- Price: $ 4950
- TOC Available:
-
Neuroblastoma Cancer Market by Diagnostics (MIBG Scan, Imaging, Urine Analysis, Biopsy), Treatment (Surgery, Chemotherapy, Radiation therapy, Stem Cell Transplant, Immunotherapy), Staging, Pipeline, Regulatory, Reimbursement - Global Forecast to 2021
Neuroblastoma is a rare extracranial solid tumor cancer that develops from immature nerve cells found in several areas of the body. It is the most common extracranial solid tumor in childhood.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Cardiac Resynchronization Therapy Market by Product Type (Cardiac Resynchronization Therapy Defibrillator and Cardiac Resynchronization Therapy Pacemaker), End User (Hospitals & Cardiac Centers and Ambulatory Surgery Centers) & Region - Global Forecasts to 2024
The cardiac resynchronization therapy market is projected to reach USD 5.1 billion by 2024, at a CAGR of 4.4%. The growth of the Cardiac Resynchronization Therapy Market is majorly driven by the increasing incidence of target diseases (primarily due to the rising geriatric population). Rising investments and support, along with technological advancements, are also contributing to the growth of this market. Prominent players in the Cardiac Resynchronization Therapy Market are Medtronic (Ireland), Abbott (US), Boston Scientific Corporation (US), MicroPort Scientific Corporation (China), BIOTRONIK (Germany), and Medico S.p.A. (Italy).
- Published: April 2019
- Price: $ 4950
- TOC Available:
-
Cell Expansion Market by Product (Consumables (Media, Sera, Reagents, Vessels), Equipment (Cell Expansion Systems, Bioreactors, Incubators)), Cell Type (Human, Animal (CHO, mESCs)), Application (Vaccines, mAbs, CGT), End User - Global Forecast to 2029
The global cell expansion market, valued at US$12.7 billion in 2023, stood at US$14.3 billion in 2024 and is projected to advance at a resilient CAGR of 13.3% from 2024 to 2029, culminating in a forecasted valuation of US$26.7 billion by the end of the period. Growth of the cell expansion market can be attributed to factors such as the booming biopharmaceutical industry, increased investments in research and development for the advancement of biopharmaceutical industry, rising need of advanced biopharmaceuticals, and increasing GMP certification for cell therapy manufacturing facilities.
- Published: March 2024
- Price: $ 4950
- TOC Available:
-
Cell Viability Assays Market by Product (MTT Assay, XTT Assay, Calcein, Resazurin, Flow Cytometry, Spectrophotometer), Cell Type (Human, Animal, Microbial), Application (Basic Research, Stem Cell, Discovery & Development) - Global Forecast to 2023
The global cell viability assays market is projected to reach USD 4.16 billion by 2023, growing at a CAGR of 8.4%. The prominent players in the cell viability assays market are Thermo Fisher Scientific (US), Bio-Rad Laboratories (US), Merck (Germany), GE Healthcare (US), BioTek Instruments (US), PerkinElmer (US), Promega Corporation (US), Biotium (US), Abcam plc (UK), Canvax (Spain), Abnova (Taiwan), G-Biosciences (US), Creative Bioarray (US), Danaher Corporation (US), and Becton, Dickinson and Company (US).
- Published: September 2018
- Price: $ 4950
- TOC Available:
-
Stem Cell Manufacturing Market by Product (Consumables, Instruments, Stem Cell Lines), Application (Research, Clinical, Cell Tissue & Banking), End User, Region (North America, Europe, APAC, Latin America, MEA) - Global Forecast to 2028
The global stem cell manufacturing market, valued at US$12.0 billion in 2022, stood at US$12.7 billion in 2023 and is projected to advance at a resilient CAGR of 11.3% from 2023 to 2028, culminating in a forecasted valuation of US$21.8 billion by the end of the period. The major factors driving the growth of this market are technological advancements in stem cell manufacturing and the increasing prevalence of genetic disorders, both of which are expected to propel market growth.
- Published: July 2023
- Price: $ 4950
- TOC Available:
-
European Home Healthcare Market By Products (Blood Glucose Meter, ECG, IV Equipment, Nutrition, Wheelchair, Fitness, Heart Rate Monitor, Pregnancy Test Kit), Services (Respiratory Therapy, Rehabilitation Therapy) & Telehealth – Forecasts to 2017
The Europe home healthcare market is segmented as products, services, telehealth, and geography. The products market is further classified into homecare testing, screening & monitoring devices, home healthcare therapeutic equipment, mobility assist & other devices, and nutrition and fitness. The home healthcare services market is further segmented into unskilled care, rehabilitation therapy, infusion therapy and respiratory therapy, while the telehealth market includes monitoring devices, services, and managed equipment services. The total market is divided into seven major countries, i.e. Germany, France, U.K., Italy Spain, Russia, and Rest of Europe (RoE).
- Published: July 2013
- Price: $ 4950
- TOC Available:
-
North American Home Healthcare Market By Product [Blood Glucose Meter, ECG, IV Equipment, Nutrition, Wheelchair, Fitness, Heart Rate Monitor, Pregnancy Test Kit], Services [Respiratory Therapy, Rehabilitation Therapy] & Telehealth - Forecasts To 2017
The North America home health care market was valued at $90.9 billion in 2012; it is poised to grow at a CAGR of 7.5% to reach $130.4 billion by 2017. Home healthcare market includes products, services, and telehealth. The home care product category comprises homecare testing, screening & monitoring devices, home healthcare therapeutic equipment, mobility assist & other devices, fitness, and nutrition products. Services include unskilled care, rehabilitation therapy, infusion therapy, and respiratory therapy, while telehealth includes home telehealth monitoring devices and telehealth services.
- Published: May 2013
- Price: $ 4950
- TOC Available:
-
Particle Therapy Market by Type (Proton Therapy, Heavy Ion), Products (Cyclotron, Synchrotron, Synchrocyclotron), Services, System (Single-room, Multi-room), Cancer Type (Pediatric, Prostate), Application (Treatment, Research) - Global Forecast to 2028
The global particle therapy market, valued at US$0.6 billion in 2022, stood at US$0.7 billion in 2023 and is projected to advance at a resilient CAGR of 8.2% from 2023 to 2028, culminating in a forecasted valuation of US$1.1 billion by the end of the period. Many factors, such as technological advancements, funding and reimbursement, strong healthcare funding, active research funding, a clear regulatory framework, growing minimally invasive procedure adoption, and the presence of key market players in developing regions are driving the growth of the particle therapy market
- Published: November 2023
- Price: $ 4950
- TOC Available:
-
Cardiovascular Therapy - Advanced Technologies And Global Market (2012 - 2017)
The research report outlines the latest developments in the cardiovascular therapy industry across the globe. The market data includes innovative technologies, key players, market trends and opportunities, drivers and challenges are clearly identified and examined.
- Published: January 2026
- Price: $ 4950
- TOC Available:
Records 11 to 20 of 50
